Page 9 - Foster Mitchell News Today

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

Investegate announcements from Novacyt S.A., Full Year 2020 Trading Update

SWM SWM”), and the Directors of Scapa Group plc (“ Scapa”) are pleased to announce that they have reached agreement on the terms of a recommended cash offer by SWM Bidco for the acquisition of the entire issued and to be issued ordinary share capital of Scapa (the “ Offer”). The Offer is intended to be effected by means of a scheme of arrangement under Part 26 of the Companies Act (the “ Scheme”).                                                         ...

an indirectly wholly-owned subsidiary of Schweitzer-Mauduit International, Inc. to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 Summary · The board of directors of AMS Holdco 2 Limited ("SWMBidco"), an indirectly wholly-owned subsidiary of Schweitzer-Mauduit International, Inc. ("SWM"), and the Directors of Scapa Group plc ("Scapa") are pleased to announce that they have reached agreement on the terms of a recommended cash offer by SWM Bidco for...

SWM SWM”), and the Directors of Scapa Group plc (“ Scapa”) are pleased to announce that they have reached agreement on the terms of a recommended cash offer by SWM Bidco for the acquisition of the entire issued and to be issued ordinary share capital of Scapa (the “ Offer”). The Offer is intended to be effected by means of a scheme of arrangement under Part 26 of the Companies Act (the “ Scheme”).                                                         ...

Investegate announcements from Medica Group PLC, Appointment of Liberum as Joint Corporate Broker

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

    Beximco Pharmaceuticals Limited ("Beximco Pharma" or "the Company", or "the Group"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces it has entered into a binding commitment with Sanofi group regarding the acquisition of a majority stake in Sanofi Bangladesh Limited ("Sanofi Bangladesh") for a base-price consideration of circa £35.5 million, to be adjusted a...

Tel: +44 (0)20 3727 1000   About Beximco Pharmaceuticals Limited Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Companys broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, ...

Investegate announcements from Medica Group PLC, Dr. Robert Lavis appointed Group Medical Director